Skip to main content
SpringerLink
Log in

Imatinib and beyond—the new CML study IV

A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia

  • Ongoing Clinical Studies
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Löffler H, Heinze B, Georgii A (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 82:398–407

    CAS  PubMed  Google Scholar 

  2. Chronic Myeloid Leukemia Trialist’s Collaborative Group (2000) Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Br J Haematol 110:573–576

    Article  PubMed  Google Scholar 

  3. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queisser W, Loffler H, Hochhaus A, Heinze B (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 84:4064–4077

    CAS  PubMed  Google Scholar 

  4. Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald J, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiß J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann HP, Heimpel H, and the German CML Study Group (2003) Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 17:1529–1537

    Article  CAS  PubMed  Google Scholar 

  5. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, Hehlmann R, Hochhaus A, Shepherd PC, Steegmann JL, Kluin-Nelemans HC, Thaler J, Simonsson B, Louwagie A, Reiffers J, Mahon FX, Montefusco E, Alimena G, Hasford J, Richards S, Saglio G, Testoni N, Martinelli G, Tura S, Baccarani M (2001) Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98:3074–3081

    CAS  PubMed  Google Scholar 

  6. Mahon FX, Delbrel X, Cony-Makhoul P, Faberes C, Boiron JM, Barthe C, Bilhou-Nabera C, Pigneux A, Marit G, Reiffers J (2002) Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20:214–220

    Article  CAS  PubMed  Google Scholar 

  7. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820–825

    PubMed  Google Scholar 

  8. Guilhot F, Chastang C, Michallet M, Guerci A, Harousseau JL, Maloisel F, Bouabdallah R, Guyotat D, Cheron N, Nicolini F, Abgrall JF, Tanzer J (1997) Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med 337:223–229

    CAS  PubMed  Google Scholar 

  9. Chronic Myeloid Leukemia Trialists’ Collaborative Group (1997) Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 89:1616–1620

    PubMed  Google Scholar 

  10. Baccarani M, Rosti G, de Vivo A, Bonifazi F, Russo D, Martinelli G, Testoni N, Amabile M, Fiacchini M, Montefusco E, Saglio G, Tura S (2002) A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 99:1527–1535

    Article  CAS  PubMed  Google Scholar 

  11. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850–858

    CAS  PubMed  Google Scholar 

  12. Kantarjian HM, Smith TL, O’Brien S, Beran M, Pierce S, Talpaz M (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 122:254–261

    CAS  PubMed  Google Scholar 

  13. Mahon FX, Montastruc M, Faberes C, Reiffers J (1994) Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon alpha. Blood 84:3592–3594

    CAS  Google Scholar 

  14. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, Schultheis B, Berger U, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC (2000) Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 95:62–66

    CAS  PubMed  Google Scholar 

  15. Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC (1995) Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol 91:126–131

    CAS  PubMed  Google Scholar 

  16. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PC, Allan NC, Hehlmann R, Goldman JM, Cross NC (1996) Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 87:1549–1555

    CAS  PubMed  Google Scholar 

  17. Reiter A, Marley SB, Hochhaus A, Sohal J, Raanani P, Hehlmann R, Gordon MY, Goldman JM, Cross NC (1998) BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha. Br J Haematol 102:1271–1278

    Article  CAS  PubMed  Google Scholar 

  18. Reiter A, Hehlmann R, Berger U, Hochhaus A, Pfirrmann M, Hasford J, Heimpel H, Hossfeld DK, Huber C, Kolb HJ, Löffler H, Pralle H, Queisser W, Gratwohl A, Tobler A, and the German CML Study Group (2002) Randomized comparison of early allogeneic related stem cell transplantation vs. IFN-based therapy in newly diagnosed chronic myeloid leukemia (CML): results of the German CML study III (abstract). Onkologie 25 [Suppl 4]:177

  19. Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb HJ, McGlave PB, Passweg JR, Rowlings PA, Sobocinski KA, Horowitz MM (1998) Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood 91:1810–1819

    CAS  PubMed  Google Scholar 

  20. Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation (1999) Monitoring treatment and survival in chronic myeloid leukemia. J Clin Oncol 17:1858–1868

    PubMed  Google Scholar 

  21. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A (1993) Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235–2238

    CAS  PubMed  Google Scholar 

  22. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan KM, Anasetti C (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962–968

    Article  CAS  PubMed  Google Scholar 

  23. Clift RA, Radich J, Appelbaum FR, Martin P, Flowers ME, Deeg HJ, Storb R, Thomas ED (1999) Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogeneic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 94:3960–3962

    CAS  Google Scholar 

  24. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF (2001) Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97:3390–3400

    CAS  PubMed  Google Scholar 

  25. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566

    CAS  PubMed  Google Scholar 

  26. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037

    CAS  PubMed  Google Scholar 

  27. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O’Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530–3539

    Article  CAS  PubMed  Google Scholar 

  28. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928–1937

    Article  CAS  PubMed  Google Scholar 

  29. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O’Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652

    CAS  PubMed  Google Scholar 

  30. O’Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, for the IRIS Investigators (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004

    Article  CAS  PubMed  Google Scholar 

  31. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y (2001) In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97:1999–2007

    CAS  PubMed  Google Scholar 

  32. La Rosee P, O’Dwyer ME, Druker BJ (2002) Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 16:1213–1219

    Article  PubMed  Google Scholar 

  33. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ (2000) Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96:3195–3199

    CAS  PubMed  Google Scholar 

  34. Topaly J, Zeller WJ, Fruehauf S (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15:342–347

    Article  CAS  PubMed  Google Scholar 

  35. Hochhaus A, Fischer T, Brümmendorf T, Schoch C, Müller MC, Merx K, Berger U, Gschaidmeier H, Hehlmann R (2002) Imatinib (Glivec®) and pegylated interferon a2a (Pegasys®) phase I/II combination study in chronic phase chronic myelogenous leukemia (CML). Blood 100:164a–165a

    Google Scholar 

  36. O’Dwyer ME, Mauro MJ, Kuyl JM, Paquette R, Sawyers CL, Druker B (2001) Preliminary evaluation of the combination of imatinib mesylate (gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML. Blood 100:846a

    Google Scholar 

  37. Mauro MJ, O’Dwyer ME, Stone RM, Walker T, Wiese A, Druker BJ (2002) Preliminary evaluation of the combination of imatinib mesylate (gleevec) with low dose ara-C as initial therapy for newly diagnosed chronic phase CML. Blood 100:165a

    Google Scholar 

  38. Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16:2190–2196

    Article  CAS  PubMed  Google Scholar 

  39. Hochhaus A, Kreil S, Corbin A, La Rosée P, Lahaye T, Berger U, Cross NC, Linkesch W, Druker BJ, Hehlmann R (2001) Roots of clinical resistance to STI-571 cancer therapy. Science 293:2163a

    Article  Google Scholar 

  40. Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A (2002) Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 16:1579–1583

    Article  CAS  PubMed  Google Scholar 

  41. Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A (2003) Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 17:1687–1694

    Article  CAS  PubMed  Google Scholar 

  42. Berger U, Engelich G, Maywald O, Pfirrmann M, Hochhaus A, Reiter A, Metzgeroth G, Gnad U, Hasford J, Heinze B, Heimpel H, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Queisser W, Hehlmann R and the German CML Study Group (2003). Interferon-treatment in the elderly with chronic myelogenous leukemia (CML): long-term results from randomized trials. Leukemia 17:1820–1826

Download references

Author information

Authors and Affiliations

  1. III. Medizinische Universitätsklinik, Klinikum Mannheim, Universität Heidelberg, Wiesbadener Str. 7–11, 68305, Mannheim, Germany

    U. Berger, G. Engelich, A. Reiter, A. Hochhaus & R. Hehlmann

Authors
  1. U. Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Engelich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Reiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Hochhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Hehlmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The German CML Study Group

Corresponding author

Correspondence to U. Berger.

Additional information

The authors listed above wrote this contribution on behalf of the German CML Study Group

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berger, U., Engelich, G., Reiter, A. et al. Imatinib and beyond—the new CML study IV. Ann Hematol 83, 258–264 (2004). https://doi.org/10.1007/s00277-003-0807-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-003-0807-x

Keywords

Search

Navigation